Starting insulin therapy in type 2 diabetic patients: Does it really matter how?

Diabetes Care

Volumn 28, Issue 2, 2005, Pages 494-495

  Davidson, Mayer B ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TREATMENT OUTCOME; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 12844269148     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.2.494     Document Type: Editorial

References (13)

1. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala R, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
2. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC: Comparison of different insulin regimens in elderly patient s with NIDDM. Diabetes Care 19:1326-1332, 1996
3. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppala P, Tulokas T, Viikari J, Taskinen M-R: Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endomnol Metab 82:4037-4043, 1997
4. Riddle MC, Schneider K, the Glimepiride Combination Group: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 21:1052-1057, 1998
5. Yki-Jarvinen H, Dressler A, Ziemen M, the HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130-1136, 2000
6. Rosenstock J, Schwartz SS, Clark CM, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631-636, 2001
7. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 26:3080-3086, 2003
8. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254-259, 2005
9. Raskin P, Allen E, Hollander P, Gabbay RA, Hu P, Bode B, Garber A, the INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265, 2005
10. 1c. Diabetes Care 26:881-885, 2003
11. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33:634-642, 1984
12. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional therapy for type II diabetes: metabolic effects during a 6-month out-patient trial. Diabetes Care 16:21-31, 1993
13. Roy R, Navar M, Palemeno G, Davidson MB: Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent. Diabetes Care 27:1741-1742, 2004